EC
LRMR icon

EcoR1 Capital’s Larimar Therapeutics LRMR Stock Holding History

EcoR1 Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-162,042
Closed -$1.44M – 49
2019
Q3 		$1.44M Buy
+162,042
New +$1.78M 0.18% 33
2016
Q1 		– Sell
-30,750
Closed -$2.43M – 40
2015
Q4 		$2.32M Buy
+30,750
New +$4.94M 0.73% 25

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

EcoR1 Capital's LRMR Position: Q4 2019 in Review

EcoR1 Capital sold out of Larimar Therapeutics (LRMR) in Q4 2019, closing a stake of 162,042 shares — an estimated $1.44M sold.

EcoR1 Capital first reported a position in LRMR in Q4 2015 and held it in 2 quarters. The position peaked at $2.32M in Q4 2015. 49 funds tracked by Wall St. Rank hold LRMR as of Q4 2019.

  • EcoR1 Capital reported no remaining Larimar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • EcoR1 Capital sold 162,042 Larimar Therapeutics shares in Q4 2019, an estimated $1.44M.
  • EcoR1 Capital first reported a position in Larimar Therapeutics in Q4 2015 and held it in 2 quarters.
  • EcoR1 Capital's Larimar Therapeutics position peaked at $2.32M in Q4 2015.
  • 49 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2019.

Based on EcoR1 Capital's 13F filing for Q4 2019, filed 14 Feb 2020.